No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TVTX Travere Therapeutic
- 7.100
- -0.230-3.14%
Close Jun 18 16:00 ET
540.52MMarket Cap-3567P/E (TTM)
7.310High6.960Low976.34KVolume7.290Open7.330Pre Close6.93MTurnover1.74%Turnover RatioLossP/E (Static)76.13MShares17.57052wk High7.30P/B398.33MFloat Cap5.12052wk Low--Dividend TTM56.10MShs Float37.040Historical High--Div YieldTTM4.78%Amplitude0.000Historical Low7.100Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Shareholders in Travere Therapeutics (NASDAQ:TVTX) Are in the Red If They Invested Five Years Ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to
Barclays Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $12
Barclays analyst Carter Gould maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 53.5% and
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Press Release: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities Health Care
Comments
$Travere Therapeutic(TVTX.US$
NEWS
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to present data on FILSPARI at prestigious medical conferences, demonstrating the potential superiority of FILSPARI over existing treatments
Analyses show FILSPARI's ability to slow kidney function decline in patients with IgA nephropathy, offering a new approach to patient care
New 48-week findings from...
NEWS
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Travere Therapeutics to present data on FILSPARI at prestigious medical conferences, demonstrating the potential superiority of FILSPARI over existing treatments
Analyses show FILSPARI's ability to slow kidney function decline in patients with IgA nephropathy, offering a new approach to patient care
New 48-week findings from...
1
$Travere Therapeutic(TVTX.US$ Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...
1
8
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.
1
$Travere Therapeutic(TVTX.US$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg